Advances in Insulin Infusion Set in the New Era of Automated Insulin Delivery: A Systematic Review
Authors' conclusion
Research in insulin infusion technology has increased in the last six years, and extended IISs have demonstrated improved overall performance, particularly in duration of wear. Paths for future products are discussed with an emphasis on understanding the existing barriers related to both technical and nontechnical issues.
Study context
- Population
- Studies of insulin infusion set (IIS) published January 2016 to July 2022 (Embase/Medline, PubMed); individuals with T1Dover 1400
- Participants
- 1,400 participants
- Comparison
- Various insulin infusion sets, including extended-wear IIS
- Outcome
- IIS wear duration, total daily dose of insulin, and IIS failure reasons/modes
Methodological detailsPRISMA
- PRISMA
Pooled result
As reported in the abstract
Publications identified
387
Eligible studies comparing various IISs
15
Wears
>53 000
Further pooled results
Glycemic control with extended IIS · seven-day use
- Clinical trials demonstrating good glycemic control throughout seven-day use
- 2
Safety
- Clinical trials demonstrating safe use of extended IISs to seven days of wear in T1D
- 3
Original publication
Advances in Insulin Infusion Set in the New Era of Automated Insulin Delivery: A Systematic Review. J Diabetes Sci Technol. Published 23 December 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →